Company Overview and News
DowDuPont Inc. (NYSE: DWDP) saw its share price dive last week, along with just about every other equity on the market — or so it seemed. The company’s shares dropped 5.6% last week to take the stock down by 16.2% for the year to date.
JBK MTSI PG CATR GSC CAT TFG DWDP GSJ GS GLSSP GJS MMM
The index suffered a particularly dismal week, weighed down by surging bond yields. Worries about slowing global growth also plagued investors after the IMF cut global forecasts. Lingering trade tensions between the United States and China also made their presence felt. Shares of tech majors also suffered sharp reverses.
LMT DUKH CATR CAT WBA DUK UTX WMT DWDP JNJ BOE MSFT INTC BA
Stocks were looking to open lower on Thursday after a sharp sell-off on Wednesday took the Dow Jones industrials down 831 points and the S&P 500 down almost 95 points. That said, S&P and Dow futures bounced handily as inflation pressure in the Consumer Price Index came in softer than expectations. While the markets are still near all-time highs, investors have seen lower upside from buying immediately after the big market pullbacks in 2018 than in prior years.
EIX DB AINC COST ANF DWDP ESL HLF BLK 7018 CME TRI CLS GPS URBN GDDY
Goldman Sachs Group Inc. (NYSE: GS) saw its share price rise a bit last week, but the gain was not enough to lift the stock out of the Dow cellar. Goldman’s shares added 0.66% last week, but the stock is still down 11.4% for the year to date.
WMT GLSSP MS MMM PRU JBK TFG PFK BRK.A PRH PJH WFCNP MTSI PG GS WFC GSC DWDP GSJ GJS
The quarter-end baby! We all look and wait for a big dividend income month and September usually never fails. The leaves are changing colors, the temperature is dropping and I have a sweatshirt on. Sitting here with a nice cup of joe and looking at the dividend income that flowed into my account. Blessed beyond belief everyone. Now let's grab that cup of coffee and see my September dividend income results!
LMT BLT D BHPBF DWDP NSC MAT ISBA MYBF BHP KHC BBL BHP BHPLF DAL MCD
Looking for broad exposure to the Materials - Broad segment of the equity market? You should consider the Fidelity MSCI Materials Index ETF (FMAT - Free Report) , a passively managed exchange traded fund launched on 10/21/2013.
FMAT PX FIDU FSLR ECL DWDP
Goldman Sachs Group Inc. (NYSE: GS) shouldered aside its competitors to assume the role of the worst-performing Dow Jones industrials stock for the year to date. The big bank’s stock dropped 4.7% last week, and shares are down 12% for the year to date.
JBK MTSI PG GSC TFG DWDP WMT GSJ GS GLSSP GJS MMM
September 28, 2018: Markets opened lower Friday and spent virtually the whole day hugging one side or the other of the break-even line. Consumer spending rose in August, but at a slower pace than previously and inflation on a PCE basis dropped from 2.3% to 2.2%. Consumer sentiment also came in a bit below expectations but remains solid near record highs. Telecoms and utilities did all they could to keep shares in the green, but financial services and basic materials stocks were fighting them all the way.
JBK GSC TFG DWDP GSJ GS GLSSP BOE INTC BA GJS
The Dow suffered a tough week, weighed down by trade tensions and the Fed’s third rate hike for the year. The latest set of U.S.-China tariffs came into effect on Monday, effectively ruling out proposed trade talks between the two counties. By Wednesday, the Fed’s fresh rate hike had dampened investor sentiment. The blue-chip index was only able to rebound on Thursday, buoyed by a raft of bullish economic data.
IBM GEC GE TRV CAT UTX DWDP NKE BOE CVX GPN AAPL GNE BA MCD
The Dow Jones Industrial Average midday Thursday was trading near session highs, with nearly all of its 30 components advancing. In fact, 29 out of the 30 Dow components were trading in positive territory, led by Apple Inc. AAPL, +2.50% which was up $4.84, or 2.2%, contributing about 33 points to the price-weighted blue-chip index. Only shares of DowDuPont Inc. DWDP, -1.96% were lower. The Dow DJIA, +0.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET